DXB 1.64% 30.0¢ dimerix limited

Maybe it’s not so odd in regards to the patients who’s kidneys...

  1. 6,423 Posts.
    lightbulb Created with Sketch. 5265
    Maybe it’s not so odd in regards to the patients who’s kidneys aren’t as damaged (so less albuminuria to reduce). Remembering that DMX-200 works on CCR2 receptors that inhibit inflammation, if that has occurred as a legacy effect in the kidneys of these patients with less damage & has a longer lasting effect, which Prof Packham mentioned if the legacy effect had occurred then it’s possible that 12 weeks on DMX-200 possibly could have changed the course of the disease.

    This is what I meant by clinical significance RL, & a good thing we have that crossover design. So this could actually be a positive for treating patients who aren’t as sick with DMX-200. We don’t know yet, but Professor Packham did say they treat at 30mg/mmol (macro albuminuria) and not to do so, would be negligent.

    Many questions, fingers crossed
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
30.0¢
Change
-0.005(1.64%)
Mkt cap ! $164.5M
Open High Low Value Volume
31.0¢ 31.0¢ 30.0¢ $818.6K 2.683M

Buyers (Bids)

No. Vol. Price($)
15 1874183 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 10850 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
30.0¢
  Change
-0.005 ( 1.64 %)
Open High Low Volume
31.0¢ 31.0¢ 30.0¢ 640607
Last updated 15.54pm 28/03/2024 ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.